This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics, 2012; 9: 311-20. PMID: 22990110ScullyOJBayBHYipGYuYBreast cancer metastasisCancer Genomics Proteomics2012931120PMID: 22990110Search in Google Scholar
Van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res 2011; 728: 23-34. doi: 10.1016/j.mrrev.2011.05.002Van ZijlFKrupitzaGMikulitsWInitial steps of metastasis: cell invasion and endothelial transmigrationMutat Res2011728233410.1016/j.mrrev.2011.05.002402808521605699Open DOISearch in Google Scholar
Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res 2018; 10: 5329-38. doi: 10.2147/CMAR.S176763XiaoWZhengSYangAZhangXZouYTangHet alBreast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based studyCancer Manag Res20181053293810.2147/CMAR.S176763622592030464629Open DOISearch in Google Scholar
Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chuang EY, et al. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS One 2012; 7: e45831. doi: 10.1371/journal.pone.0045831KuoWHChangYYLaiLCTsaiMHHsiaoCKChuangEYet alMolecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomasPLoS One20127e4583110.1371/journal.pone.0045831345805623049873Open DOISearch in Google Scholar
Weigelt B, Peterse JL, van ‚t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5: 591-602. doi: 10.1038/nrc1670WeigeltBPeterseJLvan ‚t VeerLJBreast cancer metastasis: markers and modelsNat Rev Cancer2005559160210.1038/nrc167016056258Open DOISearch in Google Scholar
Dwivedi AR, Thakur A, Kumar V, Skvortsova I, Kumar V. Targeting cancer stem cells pathways for the effective treatment of cancer. Curr Drug Targets 2019. doi: 10.2174/1389450120666190821160730. [Epub ahead of print].DwivediARThakurAKumarVSkvortsovaIKumarVTargeting cancer stem cells pathways for the effective treatment of cancerCurr Drug Targets201910.2174/1389450120666190821160730Epub ahead of print31433755Open DOISearch in Google Scholar
Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med 2013; 274: 113-26. doi: 10.1111/joim.12084RedigAJMcAllisterSSBreast cancer as a systemic disease: a view of metastasisJ Intern Med20132741132610.1111/joim.12084371113423844915Open DOISearch in Google Scholar
Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008; 8: 4521-33. doi: 10.1002/pmic.200800113SkvortsovaISkvortsovSStasykTRajuUPopperBASchiestlBet alIntracellular signaling pathways regulating radioresistance of human prostate carcinoma cellsProteomics2008845213310.1002/pmic.20080011318821526Open DOISearch in Google Scholar
Skvortsova I, Skvortsov S, Haidenberger A, Devries A, Nevinny-Stickel M, Saurer M, et al. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother 2004; 16: 372-80. doi: 10.1179/joc.2004.16.4.372SkvortsovaISkvortsovSHaidenbergerADevriesANevinny-StickelMSaurerMet alEffects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitroJ Chemother2004163728010.1179/joc.2004.16.4.37215332713Open DOISearch in Google Scholar
Buzdin A, Sorokin M, Garazha A, Sekacheva M, Kim E, Zhukov N, et al. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs. Semin Cancer Biol 2018; 53: 110-24. doi: 10.1016/j.semcancer.2018.06.003BuzdinASorokinMGarazhaASekachevaMKimEZhukovNet alMolecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugsSemin Cancer Biol2018531102410.1016/j.semcancer.2018.06.00329935311Open DOISearch in Google Scholar
Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The Reactome pathway Knowledgebase. Nucleic Acids Res 2016; 44: D481-7. doi: 10.1093/nar/gkv1351FabregatASidiropoulosKGarapatiPGillespieMHausmannKHawRet alThe Reactome pathway KnowledgebaseNucleic Acids Res201644D481710.1093/nar/gkv1351470293126656494Open DOISearch in Google Scholar
Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the Pathway Interaction Database. Nucleic Acids Res 2009; 37(Database issue): D674-9. doi: 10.1093/nar/gkn653SchaeferCFAnthonyKKrupaSBuchoffJDayMHannayTet alPID: the Pathway Interaction DatabaseNucleic Acids Res200937Database issueD674910.1093/nar/gkn653268646118832364Open DOISearch in Google Scholar
Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010; 38(Database issue): D355-60. doi: 10.1093/nar/gkp896KanehisaMGotoSFurumichiMTanabeMHirakawaMKEGG for representation and analysis of molecular networks involving diseases and drugsNucleic Acids Res201038Database issueD3556010.1093/nar/gkp896280891019880382Open DOISearch in Google Scholar
Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, Karp PD. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 2005; 6: R2. doi: 10.1186/gb-2004-6-1-r2RomeroPWaggJGreenMLKaiserDKrummenackerMKarpPDComputational prediction of human metabolic pathways from the complete human genomeGenome Biol20056R210.1186/gb-2004-6-1-r254906315642094Open DOISearch in Google Scholar
Zolotovskaia MA, Sorokin MI, Roumiantsev SA, Borisov NM, Buzdin AA. Pathway instability is an effective new mutation-based type of cancer biomarkers. Front Oncol 2018; 8: 658. doi: 10.3389/fonc.2018.00658ZolotovskaiaMASorokinMIRoumiantsevSABorisovNMBuzdinAAPathway instability is an effective new mutation-based type of cancer biomarkersFront Oncol2018865810.3389/fonc.2018.00658632878830662873Open DOISearch in Google Scholar
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-50. doi: 10.1073/pnas.0506580102SubramanianATamayoPMoothaVKMukherjeeSEbertBLGilletteMAet alGene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profilesProc Natl Acad Sci U S A2005102155455010.1073/pnas.0506580102123989616199517Open DOISearch in Google Scholar
Steinbichler TB, Savic D, Dudas J, Kvitsaridze I, Skvortsov S, Riechelmann H, et al. Cancer stem cells and their unique role in metastatic spread. Semin Cancer Biol 2019. doi: 10.1016/j.semcancer.2019.09.007. [Epub ahead of print].SteinbichlerTBSavicDDudasJKvitsaridzeISkvortsovSRiechelmannHet alCancer stem cells and their unique role in metastatic spreadSemin Cancer Biol201910.1016/j.semcancer.2019.09.007Epub ahead of print31521746Open DOISearch in Google Scholar
Velasco-Velazquez MA, Popov VM, Lisanti MP, Pestell RG. The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol 2011; 179: 2-11. doi: 10.1016/j.ajpath.2011.03.005Velasco-VelazquezMAPopovVMLisantiMPPestellRGThe role of breast cancer stem cells in metastasis and therapeutic implicationsAm J Pathol201117921110.1016/j.ajpath.2011.03.005312386421640330Open DOISearch in Google Scholar
Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep 2017; 7: 13856. doi: 10.1038/s41598-017-14364-2LiWMaHZhangJZhuLWangCYangYUnraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasisSci Rep201771385610.1038/s41598-017-14364-2565384929062075Open DOISearch in Google Scholar
Sorokin M, Kholodenko R, Suntsova M, Malakhova G, Garazha A, Kholodenko I. Oncobox bioinformatical platform for selecting potentially effective combinations of target cancer drugs using high-throughput gene expression data. Cancers (Basel) 2018; 10(10). pii: E365. doi: 10.3390/cancers10100365SorokinMKholodenkoRSuntsovaMMalakhovaGGarazhaAKholodenkoIOncobox bioinformatical platform for selecting potentially effective combinations of target cancer drugs using high-throughput gene expression dataCancers (Basel)20181010E36510.3390/cancers10100365620991530274248Open DOISearch in Google Scholar
Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA. Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia 2014; 28: 2222-8. doi: 10.1038/leu.2014.130SpirinPVLebedevTDOrlovaNNGornostaevaASProkofjevaMMNikitenkoNASilencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signalingLeukemia2014282222810.1038/leu.2014.13024727677Open DOISearch in Google Scholar
Lambaerts K, Wilcox-Adelman SA, Zimmermann P. The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol 2009; 21: 662-9. doi: 10.1016/j.ceb.2009.05.002LambaertsKWilcox-AdelmanSAZimmermannPThe signaling mechanisms of syndecan heparan sulfate proteoglycansCurr Opin Cell Biol200921662910.1016/j.ceb.2009.05.002275865619535238Open DOISearch in Google Scholar
Sayyad MR, Puchalapalli M, Vergara NG, Wangensteen SM, Moore M, Mu L, et al. Syndecan-1 facilitates breast cancer metastasis to the brain. Breast Cancer Res Treat 2019; 178: 35-49. doi: 10.1007/s10549-019-05347-0SayyadMRPuchalapalliMVergaraNGWangensteenSMMooreMMuLet alSyndecan-1 facilitates breast cancer metastasis to the brainBreast Cancer Res Treat2019178354910.1007/s10549-019-05347-031327090Open DOISearch in Google Scholar
Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012; 33: 122-8. doi: 10.1016/j.tips.2011.11.002ZhangSYuDTargeting Src family kinases in anti-cancer therapies: turning promise into triumphTrends Pharmacol Sci201233122810.1016/j.tips.2011.11.002367565922153719Open DOISearch in Google Scholar
Ying X, Huang A, Xing Y, Lan L, Yi Z, He P. Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway. Sci China Life Sci 2017; 60: 417-28. doi: 10.1007/s11427-016-0368-yYingXHuangAXingYLanLYiZHePLycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathwaySci China Life Sci2017604172810.1007/s11427-016-0368-y28251459Open DOISearch in Google Scholar
Zhao TT, Jin F, Li JG, Xu YY, Dong HT, Liu Q, et al. TRIM32 promotes proliferation and confers chemoresistance to breast cancer cells through activation of the NF-kappaB pathway. J Cancer 2018; 9: 1349-56. doi: 10.7150/jca.22390ZhaoTTJinFLiJGXuYYDongHTLiuQet alTRIM32 promotes proliferation and confers chemoresistance to breast cancer cells through activation of the NF-kappaB pathwayJ Cancer2018913495610.7150/jca.22390592907829721043Open DOISearch in Google Scholar
Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 2011; 37: 876-82. doi: 10.1016/j.ejso.2011.07.001SanpaoloPBarbieriVGenovesiDPrognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical studyEur J Surg Oncol2011378768210.1016/j.ejso.2011.07.00121824742Open DOISearch in Google Scholar
Geng SQ, Alexandrou AT, Li JJ. Breast cancer stem cells: multiple capacities in tumor metastasis. Cancer Lett 2014; 349: 1-7. doi: 10.1016/j.canlet.2014.03.036GengSQAlexandrouATLiJJBreast cancer stem cells: multiple capacities in tumor metastasisCancer Lett20143491710.1016/j.canlet.2014.03.036417787724727284Open DOISearch in Google Scholar
Antalis CJ, Uchida A, Buhman KK, Siddiqui RA. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin Exp Metastasis 2011; 28: 733-41. doi: 10.1007/s10585-011-9405-9AntalisCJUchidaABuhmanKKSiddiquiRAMigration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterificationClin Exp Metastasis2011287334110.1007/s10585-011-9405-921744083Open DOISearch in Google Scholar
Chao H, Deng L, Xu F, Yu Z, Xu X, Huang J, et al. MEX3C regulates lipid metabolism to promote bladder tumorigenesis through JNK pathway. Onco Targets Ther 2019; 12: 3285-94. doi: 10.2147/OTT.S199667ChaoHDengLXuFYuZXuXHuangJet alMEX3C regulates lipid metabolism to promote bladder tumorigenesis through JNK pathwayOnco Targets Ther20191232859410.2147/OTT.S199667650331631118679Open DOISearch in Google Scholar
Liu N, Yang Z, Liu X, Niu Y. Lymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negative. Oncotarget 2017; 8: 55534-43. doi: 10.18632/oncotarget.15022LiuNYangZLiuXNiuYLymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negativeOncotarget20178555344310.18632/oncotarget.15022558967828903439Open DOISearch in Google Scholar
Jia H, Jia W, Yang Y, Li S, Feng H, Liu J, et al. HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy. World J Surg Oncol 2014; 12: 289. doi: 10.1186/1477-781912-289JiaHJiaWYangYLiSFengHLiuJet alHER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomyWorld J Surg Oncol20141228910.1186/1477-781912-289Open DOISearch in Google Scholar
Rabinovich I, Sebastiao APM, Lima RS, Urban CA, Junior ES, Anselmi KF, et al. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. Eur J Histochem 2018; 62. doi: 10.4081/ejh.2018.2943RabinovichISebastiaoAPMLimaRSUrbanCAJuniorESAnselmiKFet alCancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinomaEur J Histochem20186210.4081/ejh.2018.2943624079030362671Open DOISearch in Google Scholar
Zhou N, Wu X, Yang B, Yang X, Zhang D, Qing G. Stem cell characteristics of dormant cells and cisplatininduced effects on the stemness of epithelial ovarian cancer cells. Mol Med Rep 2014; 10: 2495-504. doi: 10.3892/mmr.2014.2483ZhouNWuXYangBYangXZhangDQingGStem cell characteristics of dormant cells and cisplatininduced effects on the stemness of epithelial ovarian cancer cellsMol Med Rep201410249550410.3892/mmr.2014.248325119644Open DOISearch in Google Scholar
Chaterjee M, van Golen KL. Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy. Bone Marrow Res 2011; 2011: 362938. doi: 10.1155/2011/362938ChaterjeeMvan GolenKLBreast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagyBone Marrow Res2011201136293810.1155/2011/362938319994222046561Open DOISearch in Google Scholar
Steinbichler TB, Dudas J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol 2018; 53: 156-67. doi: 10.1016/j.semcancer.2018.11.006SteinbichlerTBDudasJSkvortsovSGanswindtURiechelmannHSkvortsovaIITherapy resistance mediated by cancer stem cellsSemin Cancer Biol2018531566710.1016/j.semcancer.2018.11.00630471331Open DOISearch in Google Scholar
Skvortsov S, Debbage P, Skvortsova I. Proteomics of cancer stem cells. Int J Radiat Biol 2014; 90: 653-8. doi: 10.3109/09553002.2013.873559SkvortsovSDebbagePSkvortsovaIProteomics of cancer stem cellsInt J Radiat Biol201490653810.3109/09553002.2013.87355924350919Open DOISearch in Google Scholar
Sulaiman A, McGarry S, Han X, Liu S, Wang L. CSCs in breast cancer-one size does not fit all: Therapeutic advances in targeting heterogeneous epithelial and mesenchymal CSCs. Cancers (Basel) 2019; 11. doi: 10.3390/cancers11081128SulaimanAMcGarrySHanXLiuSWangLCSCs in breast cancer-one size does not fit all: Therapeutic advances in targeting heterogeneous epithelial and mesenchymal CSCsCancers (Basel)20191110.3390/cancers11081128672146431394796Open DOISearch in Google Scholar
